Acquiring Company
Tempus AI
Acquired Company
Personalis
ChicagoMenlo ParkOtherBiotechnologyBiotechnologyHealth CareGeneticsHealth DiagnosticsBioinformaticsDescription
Tempus AI Inc is set to acquire Personalis to enhance its capabilities in precision oncology. The acquisition is driven by recent positive clinical trial results that boost Personalis's commercial outlook. Analysts have shown confidence in Tempus AI's strategy, citing significant market potential. This merger aligns with Tempus AI's goal to integrate advanced genomic technology into its operations.
Don't miss Tempus AI's next move
Get an email the moment Tempus AI makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Personalis?
Personalis was acquired by Tempus AI, based in Chicago. The deal was reported on August 20, 2026. Tempus AI, Inc. is a leader in artificial intelligence and precision medicine. Tempus AI is privately held and operates in Other.
When did Tempus AI acquire Personalis?
Tempus AI's acquisition of Personalis was reported on August 20, 2026. Tempus AI Inc is set to acquire Personalis to enhance its capabilities in precision oncology. The acquisition is driven by recent positive clinical trial results that boost Personalis's commercial outlook. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Personalis do?
Personalis, Inc. (NASDAQ: PSNL) is a company focused on transforming the active management of cancer through personalized testing, guiding care from diagnosis through treatment. It is publicly traded (PSNL), operating in Biotechnology, and is based in Menlo Park.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.